| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 12.749 | 32.871 | 4.723 | 27.537 | 41.668 | 7.587 |
| Total Income - EUR | - | - | - | - | 12.749 | 32.871 | 4.723 | 27.537 | 41.668 | 7.587 |
| Total Expenses - EUR | - | - | - | - | 5.057 | 3.681 | 13.514 | 19.578 | 31.262 | 10.631 |
| Gross Profit/Loss - EUR | - | - | - | - | 7.692 | 29.190 | -8.791 | 7.959 | 10.406 | -3.043 |
| Net Profit/Loss - EUR | - | - | - | - | 7.333 | 28.300 | -8.838 | 7.697 | 9.989 | -3.143 |
| Employees | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 |
Check the financial reports for the company - Allyser & Melimed Construct S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 52 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | 7.671 | 34.550 | 26.404 | 33.228 | 42.908 | 40.767 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 3.020 | 1.459 |
| Receivables | - | - | - | - | 0 | 72 | 0 | 608 | 30.827 | 31.526 |
| Cash | - | - | - | - | 7.671 | 34.478 | 26.404 | 32.620 | 9.061 | 7.782 |
| Shareholders Funds | - | - | - | - | 7.375 | 34.447 | 24.845 | 30.485 | 39.283 | 35.920 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 348 | 103 | 1.559 | 2.743 | 3.625 | 4.847 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4120 - 4120" | |||||||||
| CAEN Financial Year |
4120
|
|||||||||
Comments - Allyser & Melimed Construct S.r.l.